Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXAFI in Unresectable Non-Metastatic Hepatocellular Carcinoma
NCT00471484Phase 2Unknown
- Sponsor
- National Cancer Centre Singapore
- Start
- Mar 2007
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, doxorubicin, fluorouracil and interferon alfa-2b in hepatocellular carcinoma (HCC), sponsored by National Cancer Centre Singapore. Primary endpoint: Objective Tumor Response Rate. Status: unknown.
02
Drugs
oxaliplatindoxorubicinfluorouracilinterferon alfa-2b
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00471484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00471484.